Replies to post #302721 on Amarin Corp Plc (AMRN)

[Number sleven]

Montana, I am not a lawyer. What I gather from the glaxo teva case is that sales beyond the skinny label are now considered as inducement of infringement. The generic label is for treatment of pancreatitis not cvd. It looks like this ruling opens the door for legal action against generic companies. Board lawyers please correct me if I have this wrong.
Sleven,

[oneragman]

Montana, there is only one label for Vascepa. There is not one label for high trigs and another for CVD. That's the problem the generics have imo. The label in and of itself will induce infringement because it covers the RI patents. God I hope I am not wrong on this, because if I am correct, we are going up bigtime!

[sstyles]

Read the ruling. They are therapeutically equivalent, which based on this ruling means infringement.